Want to join the conversation?
Biopharmaceutical company $AMGN said the US FDA has accepted for review its Biologics License Application for ABP 501, a biosimilar candidate to Humira. ABP 501 could be an additional approved therapeutic option for patients with chronic inflammatory conditions if approved.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.